Puma Biotechnology Reports Q3 2026 Results and Becomes Debt-Free
Puma Biotechnology (PBYI) reported third-quarter 2026 total revenue of $55.1 million, highlighted by the company successfully clearing its remaining loan obligations to Athyrium. This payoff leaves Puma with a strong liquidity position, including $108.5 million in cash and marketable securities to fund ongoing research and development. Despite the improved balance sheet, the company faces headwinds in China, where generic competition for its breast cancer drug NERLYNX led to a $2.1 million reduction in royalty revenue and a lowered full-year guidance of $18 million to $19 million. However, clinical progress remains a bright spot as interim trial data for alisertib supports advancing the drug toward Phase III studies for specific breast cancer biomarkers. Management is focused on maintaining positive net income through expense control while balancing the commercialization of NERLYNX with the development of its next-generation oncology pipeline.
Tickers: $PBYI
Topics: clinical drug development debt payoff earnings report royalty revenue